183550-13-2

Basic information

• Product Name: 4-[3,5-bis(Trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenyl pyrido[3,2-f][1,4]oxazepine
• Synonyms: 4-[3,5-bis(Trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenyl pyrido[3,2-f][1,4]oxazepine
• CAS NO: 183550-13-2
• Molecular Weight: 480.41
• Mol File: 183550-13-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 4-[3,5-bis(Trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenyl pyrido[3,2-f][1,4]oxazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3,5-bis(Trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenyl pyrido[3,2-f][1,4]oxazepine(183550-13-2)
• EPA Substance Registry System: 4-[3,5-bis(Trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenyl pyrido[3,2-f][1,4]oxazepine(183550-13-2)

Safety Data

• Hazardous Substances Data: 183550-13-2(Hazardous Substances Data)

Upstream product

• 17277-47-3 (Z)-2-cyano-3-phenylbut-2-enoic acid ethyl ester 
• 183551-51-1 3,5-bis(trifluoromethyl)benzyl methanesulfonate 
• 713518-43-5 ethyl 2-cyano-5-(dimethylamino)-3-phenylhexa-2,4-dienoate 
• 183551-60-2 2-chloro-6-methyl-4-phenylnicotinic acid 
• 32707-89-4 3,5-bis(trifluoromethyl)benzenemethanol 

Downstream Products

• 183550-16-5 4-[3,5-bis(trifluoromethyl)benzyl]-2,3,4,5-tetrahydro-8-methyl-5-oxo-6-phenylpyrido[3,2-f] [1,4]oxazepine 9-oxide 

Relevant articles and documents

RECEPTOR AGONISTS

The present invention provides a TGR5 receptor agonist comprising a fused ring compound represented by the formula wherein ring A is an optionally substituted aromatic ring; and ring B' is a 5- to 8-membered ring having one or more substituents or a salt

PREVENTIVES/REMEDIES FOR EMOTIONAL DISORDERS

An agent for the prophylaxis or treatment of an emotional disorder, which contains the NK-1 receptor antagonist having particular properties of (1) having no serotonin uptake inhibitory effect, (2) being capable of migrating into the hypothalamus, or (3) having an inhibitory effect on micturition reflex, an agent for the prophylaxis or treatment of depression accompanied by urinary frequency, urinary incontinence and/or irritable bowel syndrome, which contains an NK-1 receptor antagonist, an agent for the prophylaxis or treatment of a mood disorder of patients with urinary frequency and urinary incontinence, and a circadian rhythm controller for the hypothalamic endocrine system are provided.

DRUGS

The present invention relates to a medicine which comprises a compound (I) of the formula:[wherein the ring M is a heterocylic ring having -N=Ca and Rb are bound to each other to form the ring A, or they are the same or different each representing a hydrogen atom or a substituent on the ring M;the rings A and B each is an optionally substituted homocycle or heterocycle, and at least one of them is an optionally substituted heterocycle;the ring C is an optionally substituted homocycle or heterocycle;the ring Z is an optionally substituted nitrogen-containing heterocycle; andn is an integer of 1 to 6] or a salt thereof in combination with a drug having an emetic action. The compounds (I) or their salts are useful as anti-emetic drugs. Particularly, vomiting caused by drugs having an emetic action can be inhibited by these compounds rapidly and safely at a low dose.